摘要
目的观察经导管肝动脉化疗栓塞术(TACE)联合射频消融(RFA)及索拉菲尼对肝癌切除术后复发患者治疗的临床价值。方法收集40例2009年12月至2014年5月肝细胞癌术后复发患者,其中20例采用TACE联合RFA和口服索拉菲尼(治疗组);20例行TACE联合RFA(对照组)。TACE联合RFA即TACE术后7 d^10 d行RFA治疗。索拉菲尼于TACE术后4 d开始口服,400 mg2次/d,若出现耐药则停药,每例患者行TACE联合RFA术不少于2次。结果治疗组中位生存时间为31.0个月,对照组中位生存时间为24.8个月,组间比较差异有统计学意义(P<0.05)。治疗组1、2、3年生存率分别为85%、70%、50%,对照组分别为80%、55%、30%。1、2、3年生存率组间比较差异均无统计学意义(P>0.05)。治疗组无进展生存期(PFS)为6.8个月,对照组PFS为5.7个月,差异有统计学意义(P<0.05)。结论 TACE联合RFA和口服索拉菲尼能延长肝癌切除术后复发患者的总生存期及PFS。
Objective To assess the clinical value of transcatheter arterial chemoembolization（TACE） together with radiofrequency ablation（RFA） and sorafenib in treating recurrent hepatocellular carcinoma（HCC） after surgery. Methods A total of 40 patients with recurrent HCC after surgery, who were encountered at authors＇ hospital during the period from December 2009 to May 2014, were collected. The patients were divided into the study group（n=20） receiving TACE combined with RFA and sorafenib and the control group（n=20） receiving TACE plus RFA. Within 7-10 days after TACE, RFA was carried out. In the study group, oral sorafenib therapy（400 mg, two times everyday） started at 4 days after TACE. Withdrawal of sorafenib would be ordered if drug resistance occurred. Each patient underwent TACE combined with RFA not less than two times. Results The median survival time of the study group and the control group was 31.0months and 24.8 months respectively, and statistically significant difference existed between the two groups（P〈0.05）. The one- year, 2- year and 3- year survival rates of the study group were 85%, 70% and 50%respectively, while the one- year, 2- year and 3- year survival rates of the control group were 80%, 55% and30% respectively; the differences between the two groups were not statistically significant（P〉0.05）. The progression free survival（PFS） time of the study group and the control group was 6.8 months and 5.7 months respectively, the difference between the two groups was statistically significant（P〈0.05）. Conclusion TACE combined with RFA and sorafenib can prolong the overall survival time and the progression free survival time of patients with recurrent HCC after surgery.
出处
《介入放射学杂志》
CSCD
北大核心
2015年第12期1067-1071,共5页
Journal of Interventional Radiology
关键词
化疗栓塞术
射频消融
索拉菲尼
肝细胞肝癌
外科切除
chemoembolization
radiofrequency ablation
sorafenib
hepatocellular carcinoma
surgical resection
